Series: Companies Shaping the Future
Today’s company: Owkin
The hard part is not building AI. It is getting useful medical insight from data that is scattered, sensitive, and hard to share.
That is the hidden problem Owkin is tackling.
Its work sits at the meeting point of machine learning and life sciences, where hospitals, researchers, and drug teams need better answers but cannot easily pool data in one place.
The customer is likely pharma and research groups, and also healthcare partners that need stronger models and better evidence. The pain point is slow, fragmented discovery and limited access to high-quality patient data. They pay for tools that can help find patterns, support research, and reduce wasted effort.
What makes this hard to scale is not just the code. It is trust, data access, and proving that the output is useful in a real clinical setting. If that works, the model can scale across many use cases. If not, it stays stuck in pilots.
Is the real moat in the model itself, or in the ability to unlock data that others cannot?
#AI #HealthTech #MachineLearning #LifeSciences #DataInfrastructure #Pharma #DigitalHealth
I like how this shows patient impact as a shared effort across the whole organization - from research and AI to manufacturing and project leadership. When people can see how their work connects to the purpose, it creates not only stronger innovation, but also pride, orientation and a shared sense of impact.